Lighthouse Investment Partners LLC Takes $646,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

Lighthouse Investment Partners LLC purchased a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRNFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 86,651 shares of the company’s stock, valued at approximately $646,000. Lighthouse Investment Partners LLC owned about 0.09% of Acelyrin as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SLRN. FMR LLC boosted its holdings in Acelyrin by 20.2% in the third quarter. FMR LLC now owns 8,961,726 shares of the company’s stock worth $89,914,000 after purchasing an additional 1,505,488 shares during the last quarter. Decheng Capital LLC bought a new position in Acelyrin in the fourth quarter worth approximately $10,227,000. Kynam Capital Management LP bought a new position in Acelyrin in the third quarter worth approximately $12,204,000. Walleye Capital LLC bought a new position in Acelyrin in the third quarter worth approximately $4,550,000. Finally, Vontobel Holding Ltd. bought a new position in Acelyrin in the fourth quarter worth approximately $2,429,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on SLRN shares. Wells Fargo & Company increased their price target on shares of Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 21st. HC Wainwright raised their price objective on shares of Acelyrin from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Acelyrin presently has a consensus rating of “Hold” and a consensus target price of $12.80.

Read Our Latest Report on Acelyrin

Acelyrin Stock Performance

Shares of NASDAQ SLRN opened at $4.71 on Tuesday. The company has a market cap of $466.43 million and a P/E ratio of -1.98. The firm’s fifty day moving average is $4.76 and its two-hundred day moving average is $6.51. Acelyrin, Inc. has a 52-week low of $3.91 and a 52-week high of $29.88.

Acelyrin (NASDAQ:SLRNGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.57. As a group, analysts forecast that Acelyrin, Inc. will post -3.33 EPS for the current fiscal year.

About Acelyrin

(Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

Further Reading

Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRNFree Report).

Institutional Ownership by Quarter for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.